On 10/21/24, Editas Medicine Inc (NASDAQ: EDIT) stock enjoyed a major increase of 11.9%, closing at $3.76. Moreover, exceptionally high trading volume at 244% of normal accompanied the advance. The stock has risen 17.9% during the last week but has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, EDIT is expected to continue to be Value Creation neutral.
Editas Medicine has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Editas Medicine has a neutral Appreciation Score of 48 but a very low Power Rating of 3, resulting in the Lowest Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment